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Background: CF diagnoses are increasingly made in adulthood. Sweat tests (SWT)
are routine in paediatrics but less common in adult medicine. A telephone survey of
UK adult CF centres showed that one out of 16 held a diagnostic SWT clinic. All
others performed SWT on an adhoc basis by biochemists (n = 9), paediatric teams
(n = 4) and clinical nurse specialists (CNS, n = 3).
Objectives: To audit a newly introduced CF CNS run formal SWT clinic at the
Royal Brompton Hospital (RBH) Adult CF Unit. Three SWT clinics are held per
month. The Wescor Macroduct system is used and national guidelines followed.
Results: The service has received 83 referrals over 25 months (males 49%;
median age (range): 36 yrs (16−76 yrs); 18% (n = 15) did not attend appointments).
Referrals were received from: general practitioners n = 16 (19%) and other hospitals
n = 31 (37%); other referrals were from non-CF RBH colleagues. Patients had 2
simultaneous tests (total 136 tests). 3% (n = 4) tests were unsuccessful (x1 SWT on
two patients due to insufﬁcient volume and x2 SWT on one patient who interfered
with collection). 65% (n = 44) had a sweat chloride <30mmol/L. 6% (n = 4) had
a chloride >60mmol/L. After testing patients are further evaluated in the Difﬁcult
CF Diagnosis clinic. Additionally patients (n = 19) with the G551D mutation on
ivacaftor attend for initial and monitoring SWT.
Discussion: This audit shows that a CNS run adult SWT clinic is a successful
development. The clinic conforms to national guidelines with numbers exceeding
recommendations. It is expected that as respiratory physicians become aware of
atypical presentations, the demand for adult diagnostic SWT services will increase.
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Objectives: In Michigan (MI), cystic ﬁbrosis (CF) Centers-speciﬁc QNS rates
ranged from 12−25% in 2009 instead of 10% rate recommended by the CF
Foundation (CFF). That led to delayed diagnosis, psychological and ﬁnancial
burdens on families. In this study, 4 of 5 CF Centers in MI actively participated
but all ﬁve worked together on strategies to reduce QNS rates.
Methods: MI CF Centers in addition to the Michigan Department of Community
Health (MDCH) collaborated on this project. Project steps:
1. Review the current sweat testing methods and protocols employed by participat-
ing centers.
2. Invite an expert in the sweat testing ﬁeld to each center to review the sweat
testing process. A detailed report was sent to each center with recommendations
and suggestions to improve the technique, quality of sweat collection, analysis
and running of the test.
3. Sharing of the information between the CF Centers through visits by the
sweat testing personnel to share knowledge and help strengthen the relationship
between centers.
This QI project is unique since it included several strategies to address the problem
in addition to including all centers in MI. Study duration was 2 years.
Results: 778 infants were identiﬁed as positive for CF screening through the NBS
Program. The mean age at time of sweat test was 23.2 days with SD of 13.0 days
and median of 20 days. The overall QNS percent decreased from 14.4% to 9.5%
(p-value = 0.04) during the duration of the study.
Conclusion: This project provided all participating MI Centers the opportunity to
collaborate and to improve a common problem. This teamwork led to a signiﬁcant
decrease of sweat test QNS rates.
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Objectives: The aim of the study was to determine the spectrum and susceptibility
to antimicrobial agents of the microorganisms, isolated from respiratory tract (RT)
in patients with cystic ﬁbrosis.
Methods: The study includes 25 patients aged from 3 months to 32 years, treated at
UMHAT Pleven between 2009 and 2014. A total of 75 clinical specimens obtained
from the RT were analyzed. Identiﬁcation and susceptibility testing were performed
by conventional methods, VITEK 2 and mini API Systems.
Results: Bacterial ﬁndings were registered in 46 samples from 21 of the patients. A
total of 56 microbial isolates were cultured, comprising 42 clinical strains. Gram(−)
bacteria were predominant − 66.7%, followed by Gram(+) bacteria − 28.6%, and
yeasts − 4.7%. Among Gram(−) bacteria non-fermenting glucose rods are the most
common organisms detected − 8.6%: P. aeruginosa 17 strains, P. alcaligenes 2,
A. faecalis 1, A. xylosoxidans 1, O. anthropi 1. P. aeruginosa strains were isolated
from 13 patients of different ages, but the majority of patients were over 5 years of
age. P. aeruginosa showed good susceptibility to antimicrobial agents. All isolated
strains were susceptible to tobramycin, ceftazidime and meropenem, but had some
phenotype characteristics that highly distinguished them. 13/17 strains were of
mucoid phenotype. This phenotype caused 3 out of 4 deaths in the study group.
S. aureus was the most common Gram(+) organism cultured − 11 strains.
Conclusion: Microorganisms isolated from RT varies and changes when monitored
for long time. Gram(−) bacteria, especially P. aeruginosa are dominant. P. aerugi-
nosa showed unusual phenotype characteristics.
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Cystic Fibrosis (CF) is an important genetic disorder really common in Caucasian
population. Bacterial respiratory infections are the main causes of morbidity and
mortality. Pseudomonas aeruginosa is the principal pathogen of lower airways
decline. Nowadays, its diagnosis is made by culture or real-time PCR. High-
resolution nuclear magnetic resonance (NMR) spectroscopy is now a fast analytical
tool providing information regarding the metabolic proﬁles of bioﬂuids. Saliva is
an accessible bioﬂuid for the overall health. Salivary metabolites proﬁling offer an
interesting approach to identify biomarkers associated with several chronic disorders
and cancers.
The aim of this study is to improve a protocol in order to explore the feasibility
of NMR in CF, to look for intra-subject variability in salivary metabolites concen-
trations and to detect differences before and after Pseudomonas aeruginosa lung
colonization.
Methods: Saliva of 3 CF patients was collected. Patients haven’t eaten, drunk and
tooth brushing for at least 2 hours before to take sample. Three controls saliva
were obtained from healthy people. Saliva spectra were acquired by using a Bruker
Avance 500 spectrometer.
Results: Exploration of salivary spectrum is under progress. We have observed a
large amount of differences between samples. The protocol used for analyze samples
require to be improved in order to examine modiﬁcations due to Pseudomonas
aeruginosa presence.
Conclusion: Others studies have demonstrated that NMR is an efﬁcient method
to systematically evaluate bacterial infection or disease progression. In the future,
NMR could provide a potentially saliva diagnostic test in CF patients.
